Five Prime Therapeutics completes enrollment for trial

|About: Five Prime Therapeutics,... (FPRX)|By:, SA News Editor

Completed is enrollment for the 30-patient cohort of the Phase 2 part of the ongoing clinical trial evaluating cabiralizumab in patients with tenosynovial giant cell tumor, diffuse type, also known as pigmented villonodular synovitis (PVNS), an aggressive tumor confined to the synovium.

In the Phase 2 part of the trial which was begun nearly two years ago, FPRX is evaluating response rate and duration, as well as measures of pain and range of motion, in approximately 30 patients.